On August 16, 2021, Yiqiao Shenzhou, a portfolio company invested in by Qiming Venture Partners—a sub-fund backed by the mother fund managed by Yuanhe Chencun—officially listed on the ChiNext Board of the Shenzhen Stock Exchange, with stock code: 301047.

Founded in 2007, Yiqiao Shenzhou is primarily engaged in the research and development, manufacturing, and sales of biological reagents, as well as providing technical services. Its core business spans a wide range of products, including recombinant proteins, antibodies, genes, and culture media, along with services such as recombinant protein and antibody development, and bioanalytical testing. Currently, Yiqiao Shenzhou produces and offers over 47,000 ready-to-ship products, among which more than 6,000 are recombinant proteins—including 3,800 human cell-expressed recombinant protein products—enabling the company to fully meet customer demands for recombinant proteins that closely mimic the structure and properties of naturally occurring human proteins.

In addition, Yiqiao Shenzhou also offers approximately 13,000 antibodies, including around 4,600 monoclonal antibodies, covering a wide range of life science research areas. This comprehensive portfolio provides researchers with a "one-stop" solution for sourcing biological reagents and technical services—ideal for foundational research in fields such as molecular biology, cell biology, immunology, developmental biology, and stem cell studies, as well as for innovative drug development. Customers can conveniently procure multiple reagent products through a single platform, while also benefiting from pre-purchase consultations and reliable after-sales support. This approach significantly reduces procurement costs, streamlines the purchasing process, and minimizes risks associated with variations in product quality control standards across different suppliers—ensuring smoother and more efficient experiments for our clients.

To date, Yiqiao Shenzhou has established subsidiaries in the United States and Europe, with its customer base exceeding 5,000—spanning universities, research institutions, pharmaceutical R&D companies, and other domestic and international biotechnology and life science organizations. Notably, its clients include renowned institutions such as Tsinghua University, Peking University, Fudan University, the University of Pennsylvania, and Stanford University, as well as major global players like WuXi AppTec, Sanofi, and other leading domestic and international pharmaceutical and biotech firms.

At the early stage of the COVID-19 outbreak in 2020, Yiqiao Shenzhou leveraged its bioreagent R&D and manufacturing technology platform, along with its extensive R&D expertise, to swiftly develop a range of COVID-19-related biological reagents, including proteins and antibodies. These products promptly met the growing global demand from industrial and research customers for essential reagents used in basic scientific studies, drug and vaccine development, and viral diagnostics, driving rapid growth in the company’s business performance.

Since its establishment, Yiqiao Shenzhou has received investments from institutions such as Qiming Venture Partners, QingSong Capital, and Zeyu Capital. Among them, Qiming Venture Partners held 12.32% of Yiqiao Shenzhou's shares prior to its IPO, making it the largest external investor.